Leerink Partners Sticks to Its Sell Rating for Enhabit, Inc (EHAB)

Leerink Partners analyst Whit Mayo reiterated a Sell rating on Enhabit, Inc (EHAB – Research Report) on May 8. The company’s shares closed yesterday at $8.29.

According to TipRanks, Mayo is a 3-star analyst with an average return of 2.4% and a 48.74% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Pediatrix Medical Group, Acadia Healthcare, and Humana.

The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Enhabit, Inc with a $10.05 average price target.

EHAB market cap is currently $486.5M and has a P/E ratio of -6.00.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EHAB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Enhabit, Inc (EHAB) Company Description:

Enhabit Inc provides home health and hospice services in the United States. It offers care where patients prefer it: in their homes. It operates business in two segments: home health and hospice. Its home health agencies provide a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services.